21:31 , Nov 18, 2016 |  BC Week In Review  |  Company News

SciClone deal

SciClone received an unsolicited bid from a consortium led by ABM Management Ltd. and GL Capital Management GP Ltd. to acquire all outstanding shares not already owned for $11.18 per share in cash. The price...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

DC Bead regulatory update

BTG and partner SciClone Pharmaceuticals Inc. (NASDAQ:SCLN, Foster City, Calif.) said the China Food and Drug Administration (CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors, such as hepatocellular carcinoma (HCC). DC...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology....
01:18 , Aug 29, 2014 |  BC Extra  |  Company News

China approves BTG's DC Bead

BTG plc (LSE:BTG) and SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) said the China Food and Drug Administration (CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors like hepatocellular carcinoma (HCC). DC Bead is a...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

BTG, Eisai sales and marketing update

Eisai launched DC Bead in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC). Additionally, Eisai said the device was classified in the special treatment materials (STM) category...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

DC Bead regulatory update

Eisai disclosed in its 1Q13 earnings that DC Bead was approved in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC). DC Bead is approved in the U.S....
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

BTG, Ekos Corp., Nordion deal

BTG announced a pair of deals last week with Nordion and Ekos. BTG will acquire TheraSphere liver cancer therapy from Nordion for $200 million. The product, which had revenues of $48 million for the fiscal...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

DC Bead: Phase III started

Eisai disclosed in its 1Q12 earnings that it began an open-label, Japanese Phase III trial to evaluate DC Bead in patients with hypervascularized tumors or arteriovenous malformation. Eisai has rights to DC Bead from Biocompatibles...
07:00 , Oct 17, 2011 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/14 cls Acorda Therapeutics Inc. (NASDAQ:ACOR) Baird Christopher Price target Neutral 2% $21.75 Raymond Raymond lowered his target to $25 from $31. He noted...